April 13, 2018
More than 3000 cans of Fabior (tazarotene) Foam, 0.1% (NDC 51862-295-10), are being recalled by Mayne Pharma due to superpotency concerns, according to the April 11, 2018, US Food and Drug Administration (FDA) Enforcement Report.
The recall affects 100-gram cans from lot MBEB (Exp. 1/31/19). The cans were distributed across the United States.
Mayne Pharma voluntarily initiated the recall March 21, 2018. The FDA designated it a Class III recall March 30, 2018. The classification signals use of the foam is not likely to cause adverse health consequences.
Fabior Foam is a topical prescription retinoid approved for the treatment of acne.
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here